Search results for "Neoadjuvant"

showing 10 items of 161 documents

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

2021

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks fo…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyB7-H1 AntigenDisease-Free Survival03 medical and health sciences0302 clinical medicineDouble-Blind MethodStomach NeoplasmsInternal medicineMedicine and Health SciencesmedicineCarcinomaHumans030212 general & internal medicineEsophagusImmune Checkpoint InhibitorsNeoadjuvant therapyAgedAged 80 and overChemotherapybusiness.industryCancerChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapyIntention to Treat Analysis3. Good healthNivolumabmedicine.anatomical_structureChemotherapy AdjuvantCarcinoma Squamous CellFemaleEsophagogastric JunctionNivolumabbusinessAdjuvantChemoradiotherapyNew England Journal of Medicine
researchProduct

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter R…

2020

BACKGROUND Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinCetuximab03 medical and health sciences0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMedicineHumanseducationColectomyColectomyAgedNeoplasm StagingTumor Regression Gradeeducation.field_of_studybusiness.industryPerioperativeMiddle Agedmedicine.diseaseInterim analysisdigestive system diseasesNeoadjuvant Therapy3. Good healthSurgeryTolerability030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologySurgeryFemaleFluorouracilFrancebusinessTomography X-Ray Computedmedicine.drugAnnals of surgery
researchProduct

Pretherapeutic MRI for decision-making regarding selective neoadjuvant radiochemotherapy for rectal carcinoma: interim analysis of a multicentric pro…

2012

Purpose: To study the accuracy of different cutoffs for an involved circumferential resection margin (CRM) compared with T and N categories measured by MRI as basis for selective application of neoadjuvant radiochemotherapy (nRCT) in rectal carcinoma. Materials and Methods: In a prospective multicenter observational study involving 153 primarily operated patients, the preoperative results of MRI with pathohistological findings of resected specimens were compared. Results: For a cutoff of ≤1 mm for involvement of the CRM, the accuracy of preoperative MRI was 90.9% (139/153). The negative predictive value was 98.5% (134/136). The four participating departments did not differ significantly. Fo…

AdultMalemedicine.medical_specialtySensitivity and SpecificityDecision Support TechniquesMesorectal fasciaRisk FactorsGermanyRectal carcinomamedicinePrevalenceCutoffHumansRadiology Nuclear Medicine and imagingAgedAged 80 and overbusiness.industryRectal NeoplasmsReproducibility of ResultsChemoradiotherapy AdjuvantMiddle AgedInterim analysisPrognosisPredictive valueNeoadjuvant TherapyTreatment OutcomeCircumferential resection marginObservational studyFemaleCutoff pointRadiologybusinessJournal of magnetic resonance imaging : JMRI
researchProduct

Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial

2018

Abstract Background It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study. Methods This prospective multicentre observational study included patients with stage cT2–4 rectal cancer, with any cN and cM0 status. Carcinomas in the middle and lower third that were 1 mm or less from the mesorectal fascia, all cT4 tumours, and all cT3 tumours of the lower third were classified as high risk, and these patients received nCRT followed by total mesorectal excision (TME). All other carcinomas with a minimum distance of more than 1 mm from the mesore…

AdultMalemedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatment030230 surgeryDisease-Free Survival03 medical and health sciences0302 clinical medicineCarcinomamedicineHumansProspective StudiesStage (cooking)Prospective cohort studyNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overRectal Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)ChemoradiotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyEuropeSurvival RateTreatment Outcome030220 oncology & carcinogenesisFemaleSurgeryRadiologyNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up StudiesBritish Journal of Surgery
researchProduct

Accuracy of CT colonography in the preoperative staging of colon cancer: a prospective study of 217 patients

2019

Aim The purpose of the present study was to evaluate the accuracy of computed tomography colonography (CTC) in the preoperative localization and TN staging of colon cancer. CTC can be an effective technique for preoperative evaluation of colon cancer and could facilitate the selection of high-risk patients who may benefit from neoadjuvant chemotherapy. Method This was a prospective observational study conducted at a single tertiary-care centre. It involved 217 patients (225 tumours) who had colon cancer and underwent preoperative CTC and elective colectomy. The radiologist determined the TNM stage using postprocessing software with multiplanar images and virtual colonoscopy. The following c…

AdultMalemedicine.medical_specialtyVirtual colonoscopyColorectal cancermedicine.medical_treatmentColonoscopySensitivity and SpecificitySurgical planning03 medical and health sciences0302 clinical medicineCT-Colonography Colon cancer Preoperative stagingComputed Tomography ColonographyPreoperative CaremedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingColectomyAged 80 and overmedicine.diagnostic_testbusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesNeoadjuvant Therapy030220 oncology & carcinogenesisColonic NeoplasmsFemale030211 gastroenterology & hepatologyRadiologybusinessColonography Computed TomographicColorectal Disease
researchProduct

Residual urine volume after total mesorectal excision: an indicator of pelvic autonomic nerve preservation? Results of a case-control study.

2004

Objective  The rate of bladder dysfunctions after total mesorectal excision (TME) for rectal cancer can be decreased by bilateral pelvic autonomic nerve preservation (PANP). However, it is not clear yet, how often partial nerve impairment may lead to bladder dysfunction. It was the aim of a case-control study, to examine the residual urine volume in patients before and after TME with and without complete PANP, in order to clarify, whether this parameter allows conclusions on the quality of PANP. Patients and methods  Regarding bladder function, a case group (n = 26) without complete PANP was compared with a control group (n = 26) with complete identification and nerve preservation according…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrinary systemRisk AssessmentPelvisAge DistributionPostoperative ComplicationsReference ValuesmedicineHumansAutonomic PathwaysProspective StudiesSex DistributionUrinary Bladder NeurogenicNeoadjuvant therapyNeurogenic bladder dysfunctionColectomyAgedProbabilityAged 80 and overAutonomic nervebusiness.industryRectal NeoplasmsIncidenceGastroenterologyCase-control studyOdds ratioMiddle Agedmedicine.diseaseUrination DisordersTotal mesorectal excisionSurgeryUrodynamicsQuartileCase-Control StudiesFemalebusinessFollow-Up StudiesColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Posit…

2015

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, …

AdultOncologyCancer Researchmedicine.medical_specialtyStromal cellReceptor ErbB-2medicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast NeoplasmsCarboplatinchemistry.chemical_compoundLymphocytes Tumor-InfiltratingPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansAgedRandomized Controlled Trials as TopicChemotherapybusiness.industryTumor-infiltrating lymphocytesCancerFOXP3Middle AgedPrognosismedicine.diseaseNeoadjuvant TherapyCarboplatin3. Good healthCD8AGene Expression Regulation NeoplasticOncologychemistryChemotherapy AdjuvantCXCL9FemalebusinessJournal of Clinical Oncology
researchProduct

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95…

AdultOncologyEribulin Mesylatemedicine.medical_specialtyeribulin mesylatemedicine.medical_treatmentTriple Negative Breast Neoplasmschemotherapytriple negative metastatic breast cancer03 medical and health scienceschemistry.chemical_compound0302 clinical medicineadjuvantInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapy; Efficacy outcomes; Eribulin mesylate; Toxicity outcomes; Triple negative metastatic breast cancerProgression-free survivalFuransAdverse effectTriple-negative breast cancerAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapybusiness.industryRetrospective cohort studyGeneral MedicineKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerNeoadjuvant TherapyProgression-Free SurvivalchemistryChemotherapy AdjuvantFemale030211 gastroenterology & hepatologytoxicity outcomesefficacy outcomeschemotherapy; efficacy outcomes; eribulin mesylate; toxicity outcomes; triple negative metastatic breast cancer; adult; aged; aged; 80 and over; antineoplastic combined chemotherapy protocols; chemotherapy; adjuvant; female; furans; humans; ketones; middle aged; neoadjuvant therapy; neoplasm staging; progression-free survival; retrospective studies; triple negative breast neoplasmsbusinessResearch PaperEribulinInternational Journal of Medical Sciences
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study

2015

Abstract Study Objective To assess the feasibility of total robotic radical surgery (TRRS) in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT). Design A prospective (preplanned) study of a nonrandomized controlled trial (Canadian Task Force classification level 2). Setting Catholic University of the Sacred Hearth, Rome, Italy. Patients Between September 2013 and January 2016, a total of 40 patients with LACC (Federation Internationale de Gynecologie et d'Obstetrique stage IB2–III) were enrolled in the study. Interventions Robotic radical hysterectomy (RRH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 weeks after CT/RT. The …

AdultUterine Cervical Neoplasmmedicine.medical_specialtymedicine.medical_treatmentUterine Cervical NeoplasmsHysterectomyPostoperative ComplicationsmedicineRadical hysterectomyHumansProspective StudiesCervical cancer; Laparoscopy; Neoadiuvant chemoradiation; Radical hysterectomy; Adult; Aged; Carcinoma; Squamous Cell; Chemoradiotherapy; Adjuvant; Cisplatin; Feasibility Studies; Female; Humans; Italy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Postoperative Complications; Prospective Studies; Uterine Cervical Neoplasms; Hysterectomy; Laparoscopy; Lymph Node ExcisionRadical surgeryRadical HysterectomyProspective cohort studyNeoadjuvant therapyAgedCervical cancerHysterectomybusiness.industryMedicine (all)Obstetrics and GynecologyLaparoscopic Radical HysterectomyPerioperativeChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseNeoadjuvant TherapySurgeryFeasibility StudieProspective StudieSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyCervical cancerNeoadiuvant chemoradiationCarcinoma Squamous CellFeasibility StudiesLymph Node ExcisionLymphadenectomyFemaleLaparoscopyPostoperative ComplicationCisplatinNeoplasm Recurrence LocalbusinessHuman
researchProduct